Inspira Pharma is developing a potential new therapy for COVID-19. The active molecules being tested are plant-based and have shown an ability to destroy the SARS-CoV-2 virus in the lab. Funds raised will be used to test clinical formulations and prove safety and efficacy in humans.
There's still no cure for COVID-19. “Vaccines will never be a 100% solution... it’s almost certain that we will continue to have people falling seriously ill with COVID for a long time, perhaps forever.” (Prof. Peter Horby, Oxford University).
Our team were conducting research into wound care with another biomedical firm but, when COVID-19 hit, they looked to pivot the technology through Inspira to tackle this challenge. They discovered that the molecules in the formulations might be able to attack the SARS-CoV-2 spike proteins.
In lab tests, our formulations killed over 95% of the SARS-CoV-2 virus; now we want to test whether a COVID-19 patient could safely inhale our formulations directly into the lungs as an effective treatment.
So far we've secured cornerstone investment from biotech angel investors & a Singaporean VC, we’re now offering retail investors the opportunity to invest alongside them! Funds raised will be used to test our formulations as a potential new drug. This will include further laboratory analysis, safety testing, & preparation for human trials.
We believe our technology has further potential for a number of other respiratory infections. We plan to test our formulations against cystic fibrosis, influenza & the common cold in coming months.
COVID-19 thrives in a crowd, wouldn't it be amazing if the crowd could come together to fight back against the pandemic.